Quest Gains New York Approval for Haystack MRD Cancer Monitoring Test
The approval allows Quest Diagnostics to offer its minimal residual disease test for patients in all 50 states.
Read MorePosted by CLP Edit Staff | Jun 24, 2026 | Cancer, Company News |
The approval allows Quest Diagnostics to offer its minimal residual disease test for patients in all 50 states.
Read MorePosted by CLP Edit Staff | Jun 18, 2026 | Compliance |
The settlement resolves claims that Advanced Pathology Solutions provided illegal incentives to gastroenterology practices and performed unnecessary medical testing.
Read MorePosted by Alyx Arnett | Jun 18, 2026 | Information Technology, Sponsored |
Despite increasing demands, many laboratories continue to rely on outdated laboratory information systems that were built for a different era of healthcare.
Read MorePosted by CLP Edit Staff | Jun 18, 2026 | Compliance, Lab Management |
A new federal bill, the Enhancing CLIA Act of 2026, seeks to update oversight of laboratory-developed tests following a 2025 court decision, proposing a two-year delay for new requirements and a voluntary pathway for existing device clearances.
Read MorePosted by CLP Edit Staff | Jun 18, 2026 | Analytical Software Systems, Digital Pathology |
The update integrates artificial intelligence into the system architecture to assist with case review, biomarker discovery, and laboratory operations.
Read More